Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Omiganan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.54 |
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 8/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omiganan SCHEMBL27824120 | 0.99 | CXCR4 (0.60) | CXCR4KISS1RNTSR2NTSR1SORT1 | |
| SCHEMBL29675079 | 0.98 | CXCR4 (0.60) | CXCR4KISS1RNTSR2NTSR1SORT1 | |
| SCHEMBL28202049 | 0.98 | CXCR4 (0.60) | CXCR4KISS1RNTSR2NTSR1SORT1 | |
| SCHEMBL29674929 | 0.96 | CXCR4 (0.59) | CXCR4KISS1ROPRM1OPRK1 | |
| SCHEMBL29675119 | 0.96 | CXCR4 (0.59) | CXCR4KISS1ROPRM1OPRK1 | |
| SCHEMBL29412263 | 0.94 | CXCR4 (0.61) | CXCR4KISS1RNTSR2NTSR1SORT1 | |
| SCHEMBL30273393 | 0.94 | CXCR4 (0.61) | CXCR4KISS1RNTSR2NTSR1SORT1 | |
| SCHEMBL29443798 | 0.91 | CXCR4 (0.60) | CXCR4KISS1RNTSR2NTSR1SORT1 | |
| SCHEMBL29367784 | 0.89 | NTSR2 (0.62) | CXCR4NTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL30498028 | 0.87 | OPRM1 (0.65) | OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260007715-A1 | WOUND CARE DEVICE | AMFERIA AB (SE) | 2026-01-08 | — | — | US | disclosed |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250381290-A1 | Antibody Conjugates and Methods of Making and Using the Same | SCHERER TECHNOLOGIES LLC R P (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320205-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| CN-105744935-B | Hydrazino-pyrrolo compounds and methods for forming conjugates | 雷德伍德生物科技股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-11439641-B2 | Pyrimidine JAK inhibitors for the treatment of skin diseases | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3694568-B1 | AMPHIPHILIC ANTIMICROBIAL HYDROGEL | AMFERIA AB (SE) | 2022-08-31 | — | — | EP | disclosed |
| US-11426465-B2 | Hydrazinyl-indole compounds and methods for producing a conjugate | Redwiid Bioscience, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220220464-A1 | CHIMERIC LYSM POYLPEPTIDES | BACTOCLEAR HOLDINGS PTE LTD (SG) | 2022-07-14 | — | — | US | disclosed |
| US-11376334-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220153696-A1 | Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2022-05-19 | — | — | US | disclosed |
| US-20220145270-A1 | Antibody Conjugates and Methods of Making and Using the Same | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2022-05-12 | — | — | US | disclosed |
| EP-3959213-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | Theravance Biopharma R&D IP, LLC (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3958969-A1 | ESTER AND CARBONATE PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11439641-B2 | Pyrimidine JAK inhibitors for the treatment of skin diseases | JAK1, JAK3, JAK2 | OPRM1 4809/4885OPRK1 3806/4885CXCR4 1174/4885 |
| US-20220153696-A1 | Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate | DNPEP, QPCT, PDS5A | OPRM1 4023/4885OPRK1 3804/4885CXCR4 2486/4885 |
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | OPRM1 379/4885OPRK1 264/4885CXCR4 404/4885 |
| US-11426465-B2 | Hydrazinyl-indole compounds and methods for producing a conjugate | HNMT, AANAT, INMT | OPRM1 2297/4885OPRK1 1309/4885CXCR4 2820/4885 |
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | OPRM1 4737/4885OPRK1 4476/4885CXCR4 2006/4885 |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, STAT1, STAT5B | OPRM1 4694/4885OPRK1 4395/4885CXCR4 1119/4885 |
| US-20250381290-A1 | Antibody Conjugates and Methods of Making and Using the Same | PFAS, FGR, FGB | OPRM1 2692/4885OPRK1 4246/4885CXCR4 3748/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | OPRM1 2121/4885OPRK1 3651/4885CXCR4 607/4885 |
| US-11376334-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | HNMT, TIAL1, HACL2 | OPRM1 3403/4885OPRK1 3289/4885CXCR4 1943/4885 |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, NCOR1, NCOR2 | OPRM1 403/4885OPRK1 714/4885CXCR4 32/4885 |
| US-20250320205-A1 | STAT6 DEGRADERS | STAT6, STAT1, STAT5B | OPRM1 4802/4885OPRK1 4564/4885CXCR4 2063/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | OPRM1 801/4885OPRK1 1288/4885CXCR4 119/4885 |
| US-20250320206-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | OPRM1 4737/4885OPRK1 4476/4885CXCR4 2006/4885 |
| US-20260007715-A1 | WOUND CARE DEVICE | CUTA, F12, F10 | OPRM1 2812/4885OPRK1 3680/4885CXCR4 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.